ALPMF Stock UPDATES Astellas Pharma Inc (ALPMF) 14.4425 08/20/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Astellas Pharma Inc (ALPMF) 14.4425 $ALPMF

Global Antifungal Therapeutics Market 2014 Trends and Opportunities New Study Now Available at MarketReportsOnline.com
PRWeb - Mon Aug 18, 8:31AM CDT
The report titled "Global Antifungal Therapeutics Market: Trends and Opportunities (2014-2019)" provides an in-depth analysis of global antifungal therapeutics market with focus on antifungal drug classes - Polyenes, Azoles, Echinocandins and Allylamines. It provides broad coverage of these classes with detailed analysis of drugs and indications in respective classes. It also assesses the key opportunities and underlying trends in the market and outlines the factors that are and will be driving the growth of the industry in the forecasted period (2014-19). Further, key players of the industry such as Merck & Co., Inc., Pfizer Inc., Astellas Pharma Inc. and Noble Corporation SCYNEXIS, Inc. are also profiled in the report.

Cancer Research UK and Cancer Research Technology Join Forces with Astellas on Autophagy to Find New Cancer Treatments
PR Newswire - Fri Aug 08, 8:00AM CDT
Cancer Research UK and its commercial arm, Cancer Research Technology ("CRT" , are to join forces with Astellas Pharma Inc. (Tokyo, President & CEO: Yoshihiko Hatanaka, "Astellas" to find new drug targets in the fight against cancer, with an initial focus on pancreatic cancer.

CANCER RESEARCH UK AND CANCER RESEARCH TECHNOLOGY JOIN FORCES WITH ASTELLAS ON AUTOPHAGY TO FIND NEW CANCER TREATMENTS
Business Wire - Fri Aug 08, 2:02AM CDT
Cancer Research UK and its commercial arm, Cancer Research Technology ("CRT" , are to join forces with Astellas Pharma Inc. (Tokyo, President & CEO: Yoshihiko Hatanaka, "Astellas" to find new drug targets in the fight against cancer, with an initial focus on pancreatic cancer.

Astellas Pharma EMEA Announces New Senior Appointments
PR Newswire Europe - Thu Aug 07, 6:26AM CDT
CHERTSEY, England, August 7, 2014 /PRNewswire/ --

Corporate Whistleblower Center Urges Physicians Who Have Proof of A Drug Company Promoting Off-Label Drug Sales in Any State to Call Them About Whistleblower Rewards
PRWeb - Thu Aug 07, 4:50AM CDT
The Corporate Whistleblower Center is urging physicians or healthcare industry insiders to call them at 866-714-6466 if they have well documented proof a pharmaceutical company is deeply involved in the promotion of an off-labeled drug. The reward for this type of information can be significant.

Global Parkinson's Disease Market 2014-2018: Key Vendors are Boehringer Ingelheim, GlaxoSmithKline, Novartis and Teva
M2 - Thu Jul 31, 5:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l95k93/global) has announced the addition of the "Global Parkinson's Disease Market 2014-2018" report to their offering. Parkinson's disease is a progressive neurodegenerative disorder characterized by damage of dopaminergic neurons located in various parts of brain including the substantia nigra. This lowers the concentration of dopamine in the striatum. A decrease in dopamine levels by 80 percent leads to the development of symptoms associated with Parkinson's disease such as tremor, bradykinesia, and muscular rigidity. It is usually diagnosed in the population aged 60 and over; however, earlier incidences have been reported. Based on the severity, it can be categorized into early stage, mid stage and late (or advanced) stage. Currently, the approved therapies provide only symptomatic relief. Levodopa is the standard drug for the treatment of Parkinson's disease; however, it is associated with the incidence of dyskinesias. Alternative surgical procedures such as bilateral globus pallidus interna stimulation and bilateral subthalamic nucleus stimulation can be used in Parkinson's disease patients under certain circumstances. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by MOA 08. Geographical Segmentation 09. Buying Criteria 10. Market Growth Drivers 11. Drivers and their Impact 12. Market Challenges 13. Impact of Drivers and Challenges 14. Market Trends 15. Trends and their Impact 16. Vendor Landscape 17. Key Late-Stage Pipeline Candidates 18. Other Prominent Vendors 19. Key Vendor Analysis 20. Other Reports in this Series Companies Mentioned: - Boehringer Ingelheim GmbH - GlaxoSmithKline plc - Novartis AG - Teva Pharmaceutical Industries Ltd. - Abbvie Inc. - Akorn Inc. - Astellas Pharma Inc. - Desitin Arzneimittel GmbH - Endo International plc - F. Hoffmann-La Roche Ltd. - H. Lundbeck A/S - Kyowa Hakko Kirin - Merck & Co. Inc. - Orion Corp. - STADA Arzneimittel AG - UCB Inc. - US WorldMeds LLC - Valeant Pharmaceuticals International Inc. For more information visit http://www.researchandmarkets.com/research/l95k93/global

Vical Reports Second Quarter 2014 Financial Results and Progress in Key Development Programs
GlobeNewswire - Thu Jul 31, 5:01AM CDT
Vical Incorporated (Nasdaq:VICL) today reported financial results for the three months and six months ended June 30, 2014. The net loss for the second quarter of 2014 was $4.0 million, or $0.05 per share, compared with a net loss of $9.9 million, or $0.11 per share, for the second quarter of 2013. Revenues for the second quarter of 2014 were $4.5 million, compared with revenues of $1.5 million for the second quarter of 2013, reflecting higher revenues from Astellas Pharma Inc. under an exclusive worldwide license of ASP0113, Vical's therapeutic vaccine designed to control cytomegalovirus (CMV) reactivation in transplant recipients.

Global Rheumatoid Arthritis Drugs Market 2014-2018
M2 - Mon Jul 28, 6:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tv2rn2/global_rheumatoid) has announced the addition of the "Global Rheumatoid Arthritis Drugs Market 2014-2018" report to their offering. RA is a chronic disease that leads to inflammation and pain in the human body's joints such as wrists, fingers, knees, feet, and ankles. In addition, it causes inflammation of the tissues that surround the joints and in other organs. The symptoms of RA begin slowly, usually just mild pain around the joints coupled with stiffness and fatigue, and in the later stages it causes inflammation of the joints. It can occur at any age, even in children, which is called juvenile arthritis. The disease is three times more common in women than in men. Genetic and environmental elements are known to contribute in the development of RA. The analysts forecast the Global Rheumatoid Arthritis Drugs market will grow at a CAGR of 4.09 percent over the period 2013-2018. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Competitive Assessment of Top Drugs 08. Five Forces Analysis 09. Market Segmentation by Category 10. Geographical Segmentation 11. Buying Criteria 12. Rate of Incidence and Prevalence 13. Pipeline Snapshot 14. Market Growth Drivers 15. Drivers and their Impact 16. Market Challenges 17. Impact of Drivers and Challenges 18. Market Trends 19. Trends and their Impact 20. Vendor Landscape 21. Key Vendor Analysis 22. Other Reports in this Series Companies Mentioned: - AbbVie Inc. - Amgen Inc. - Bristol-Myers Squibb Co. - F. Hoffmann-La Roche Ltd. - Janssen Pharmaceuticals Inc. - Pfizer Inc. - AB Science SA - Astellas Pharma Inc. - AstraZeneca plc - Biogen Idec Inc. - Boehringer Ingelheim GmbH - Celgene Corp. - Daiichi Sankyo Co. Ltd. - Eli Lilly & Co. - GE Healthcare Co. - Genmab A/S - GSK plc - Incyte Corp. - Merck & Co. Inc. - Mitsubishi Tanabe Pharma Corp. - Novartis AG - Novo Nordisk A/S - Rigel Pharmaceuticals Inc. - Sanofi - Takeda Pharmaceutical Co. Ltd. - UCB SA - Vertex Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/tv...rheumatoid

AG Gansler: Astellas Pharma US Inc. Pays $7.3 Million to Resolve False Claims Act Allegations Related to Marketing of Antifungal Agent Company promoted Mycamine to treat children without FDA approval
M2 - Mon Jul 28, 4:36AM CDT
Attorney General Douglas F. Gansler announced today that Maryland, joined by multiple states and the federal government, has settled allegations that Astellas Pharma US, Inc. (Astellas) caused false claims to be submitted to federal and state health care programs in connection with its marketing and promotion of the drug Mycamine for pediatric use. Mycamine is a sterile, lyophilized (freeze-dried) antifungal agent that was approved only for use by adults. As part of the settlement, Astellas will pay $13,583.96 to the Maryland Medicaid program.

Global Endometriosis Market 2014-2018 with Abbvie Inc., AstraZeneca plc, Bayer AG & Pfizer Inc. Dominating
M2 - Thu Jul 17, 10:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k8lcbs/global) has announced the addition of the "Global Endometriosis Market 2014-2018" report to their offering. This report covers the present scenario and the growth prospects of the Global Endometriosis market for the period 2013-2018. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of endometriosis that are available in the market. The launch of high-cost GnRH antagonist therapies such as AbbVie's Elagolix (which is in phase III trial) is expected during the forecast period. Currently, the market is being served by low-cost alternatives such as combined OCPs, NSAIDs, and progestins. Patients tend to choose low-cost alternatives, which will be a challenge to the high-cost GnRH Antagonist market. According to the report, the Global Endometriosis market is driven by a large amount of unmet need due to lack of diagnostics and lack of approved treatment options for the disease. Currently, the diagnosis is mainly through non-invasive methods where standard diagnostic procedures are not available. Thus, development of proper diagnostic tools for the early detection of the disease will increase the number of patients treated. A lack of approved drugs for the treatment of endometriosis creates a lucrative space for companies to develop new therapy options to enter the market. Further, the report states that one of the main challenges is patent expiries of endometriosis drugs which leads to loss of exclusive rights of branded products followed by the introduction of low-priced generics into the market. This poses a potential threat to the established companies that spend a huge amount on R&D. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. Key Vendors - Abbvie Inc. - AstraZeneca plc - Bayer AG - Pfizer Inc. Other Prominent Vendors - Astellas Pharma Inc. - Abbvie Inc. - Repros Therapeutics Inc. - Sanofi SA - Takeda Pharmaceuticals Co. Ltd. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Rate of Incidence and Prevalence - Market Segmentation by Type of Therapy - Market Segmentation by Route of Administration and Type of Dosage Form - Pipeline Portfolio - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/k8lcbs/global

Donna Ambrosino Joins ClearPath Vaccines Company as Chief Medical Officer
PR Newswire - Tue Jul 15, 8:00AM CDT
ClearPath Development Company (ClearPath) announced today that Donna Ambrosino, MD, has joined the company's subsidiary, ClearPath Vaccines Company (CVC), as its chief medical officer. Dr. Ambrosino will play a leading role in working with the CVC team along with its partner, Astellas Pharma Inc., to identify and evaluate vaccine candidates for potential in-licensing to development company subsidiaries, and strategic planning and development of the in-licensed products.

Myasthenia Gravis - Pipeline Review, H1 2014
M2 - Thu Jul 03, 5:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z232kc/myasthenia_gravis) has announced the addition of the "Myasthenia Gravis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Myasthenia Gravis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myasthenia Gravis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Myasthenia Gravis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Myasthenia Gravis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - GlaxoSmithKline plc - Grifols, S.A. - Astellas Pharma Inc. - Nutra Pharma Corporation - Alexion Pharmaceuticals, Inc. - Alnylam Pharmaceuticals, Inc. - Cytokinetics, Inc. - HanAll Biopharma Co., Ltd. - CuraVac, Inc. - Biokine Therapeutics Ltd. - Toleranzia AB For more information visit http://www.researchandmarkets.com/research/z2...nia_gravis

Visceral Pain - Pipeline Review, H1 2014
M2 - Fri Jun 27, 5:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/37cr4s/visceral_pain) has announced the addition of the "Visceral Pain - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Visceral Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Visceral Pain and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Visceral Pain - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Visceral Pain pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Nektar Therapeutics - Astellas Pharma Inc. - Grunenthal GmbH - Trevena, Inc. - Hydra Biosciences, Inc. - GIcare Pharma Inc - Istituto Italiano di Tecnologia For more information visit http://www.researchandmarkets.com/research/37...ceral_pain

Chronic Back Pain - Pipeline Review, H1 2014
M2 - Wed Jun 25, 4:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c6d5mq/chronic_back_pain) has announced the addition of the "Chronic Back Pain - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Back Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Back Pain and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic Back Pain - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic Back Pain pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Adynxx, Inc. - Akron Molecules GmbH - Astellas Pharma Inc. - Collegium Pharmaceutical, Inc. - Endo Pharmaceuticals Inc. - Grunenthal GmbH - Pfizer Inc. - Teva Pharmaceutical Industries Limited For more information visit http://www.researchandmarkets.com/research/c6..._back_pain

Veloxis Announces Positive Two-Year Results from Pivotal Phase 3 Study of Envarsus® XR (tacrolimus extended-release tablets) in de novo Kidney Transplant Patients
PR Newswire - Mon Jun 23, 10:50AM CDT
Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that two-year results of the pivotal Phase 3 clinical trial, Study 3002, of Envarsus® XR (tacrolimus extended-release tablets) in de novo kidney transplant patients continued to demonstrate non-inferiority compared to tacrolimus capsules (Prograf®; Astellas Pharma). Data will be presented in a late-breaker session at the World Transplant Congress (WTC) in San Francisco, entitled "Two-Year Results of Envarsus (Once-daily MeltDose Tacrolimus Tablets) vs Prograf (Twice-daily Tacrolimus Capsules): A Phase 3, Double-Blind, Double-Dummy, Multi-Center, Prospective, Randomized Study" at 6:30 p.m. PDT on July 27th.

Astellas Announces Health Canada's Approval of Advagraf® as a Once-daily Immunosuppressive Therapy for Liver Transplant Patients
CNW Group - Thu Jun 19, 8:00AM CDT
Therapy helps simplify medication regimen for liver transplant recipients

Renal Cell Carcinoma - Pipeline Review, H1 2014
M2 - Thu Jun 12, 3:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5lwrwg/renal_cell) has announced the addition of the "Renal Cell Carcinoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Renal Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Renal Cell Carcinoma and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Renal Cell Carcinoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Renal Cell Carcinoma and enlists all their major and minor projects Companies Mentioned: - Bristol-Myers Squibb - Boehringer Ingelheim - Kyowa Hakko Kirin - Amgen - Eli Lilly and Company - GlaxoSmithKline - Seattle Genetics - Genentech - Agenus - Merck & Co - Celltrion - Astellas Pharma - ImmunoGen - Ono - Pfizer - Taiho - Onyx - Bayer - Advaxis - Hemispherx - Celldex Therapeutics, Inc. - Active Biotech AB - Lorus Therapeutics Inc. - Lpath, Inc. - Bionomics Limited - Flamel Technologies S.A. - Mologen AG - Threshold Pharmaceuticals, Inc. - Colby Pharmaceutical Company - Wilex AG For more information visit http://www.researchandmarkets.com/research/5lwrwg/renal_cell

Astellas Pharma Returns to 'Give Kids The World' and Expands Partnership with Starlight Children's Foundation to Brighten the Lives of Young Patients & Their Families
PR Newswire - Wed Jun 11, 8:00AM CDT
About 1,400 Astellas Pharma employees will be descending on Give Kids The World (GKTW) for the second time to tackle projects ranging from landscaping to assembling furniture as well as resurfacing parking lots and roads. This year, Astellas is bringing an even bigger volunteer group than the record-breaking Astellas team that volunteered in 2012 (pictured). GKTW is a 70-acre resort that provides free weeklong vacations to children with life-threatening illnesses and their families.

Mantle Cell Lymphoma - Pipeline Review, H1 2014
M2 - Wed Jun 11, 5:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/p6jdmb/mantle_cell) has announced the addition of the "Mantle Cell Lymphoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Mantle Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mantle Cell Lymphoma and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Mantle Cell Lymphoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Mantle Cell Lymphoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects Companies Mentioned: - Amgen Inc. - Eli Lilly and Company - GlaxoSmithKline plc - Gilead Sciences, Inc. - Merck & Co., Inc. - Infinity Pharmaceuticals, Inc. - Piramal Enterprises Limited - Millennium Pharmaceuticals, Inc. - Novartis AG - Astellas Pharma Inc. - BioMarin Pharmaceutical Inc. - ImmunoGen, Inc. - Pfizer Inc. - Astex Pharmaceuticals, Inc. - Teva Pharmaceutical Industries Limited - Cell Therapeutics, Inc. - Celgene Corporation - Onyx Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/p6...antle_cell

Diffuse Large B-Cell Lymphoma - Pipeline Review, H1 2014
M2 - Tue Jun 10, 4:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ch2twj/diffuse_large) has announced the addition of the "Diffuse Large B-Cell Lymphoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Diffuse Large B-Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diffuse Large B-Cell Lymphoma and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned: - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - Amgen Inc. - Sanofi - AstraZeneca PLC - GlaxoSmithKline plc - Seattle Genetics, Inc. - Genentech, Inc. - MedImmune, LLC - Gilead Sciences, Inc. - Merck & Co., Inc. - Infinity Pharmaceuticals, Inc. - Celltrion, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Astellas Pharma Inc. - ImmunoGen, Inc. - Genmab A/S - Celgene Corporation - Incyte Corporation - Immunomedics, Inc. - Idera Pharmaceuticals, Inc. - Portola Pharmaceuticals, Inc. - Pharmacyclics, Inc. For more information visit http://www.researchandmarkets.com/research/ch...fuse_large




Scroll down for more posts ▼

Top 10 Most Recent News Articles

S&P Global's December 8 Talk Puts Guidance in Focus

Updated Category News Views 54

A 35-minute fireside chat can be a whole lot of nothing, or it can leave a useful breadcrumb trail for shareholders willing to listen closely. S&P Global has put December 8, 2026 on the calendar, when Chief Executive Officer Martina Cheung is scheduled to appear at Goldman Sachs' 2026 Financial Services Conference in New York. Her slot runs from 5:00 p.m. to 5:35 p.m....

Continue Reading
California Rideshare Data Exposes an Insurance Gap

Updated Category News Views 52

Three California counties carried an outsized share of rideshare traffic, and the insurance fine print is where this story gets uncomfortable. A review by Mendez & Sanchez says Los Angeles, San Francisco, and San Diego counties accounted for nearly two-thirds of statewide rideshare trips between September 2019 and August 2020. That is an old snapshot, sure, but it points...

Continue Reading
Nevada’s Space Academy Bid Has Assets, Not a Win Yet

Updated Category News Views 29

Desert acreage and a moon-landing backstory make for a handsome pitch, but Nevada is still standing at the starting line. The state has submitted its official response to NASA’s Request for Information for a proposed United States Space Academy, and the new promotional video is meant to show why the Silver State belongs in the conversation. Fair enough. There is real...

Continue Reading
Mars Sets $2 Billion Debt Tender With Kellanova Notes

Updated Category News Views 124

A two-billion-dollar vacuum cleaner just switched on inside Mars’s debt stack, and the timing is anything but casual. On November 20, Mars fixed the pricing for cash tender offers spanning selected Mars and Kellanova senior notes, with holders facing a 5:00 p.m. New York deadline that same day. This is the kind of filing that looks like bond-market plumbing until you...

Continue Reading
TEN Holdings Raises $1.0 Million as Dilution Looms

Updated Category News Views 66

A Small Raise With a Loud Message Nothing says “we need room to breathe” quite like selling 1,492,500 new shares for $0.67 apiece. TEN Holdings closed a roughly $1.0 million gross equity offering on November 20, 2026, and investors in NASDAQ:XHLD ought to look at this for what it is: a modest cash infusion that comes with immediate dilution. The company gets capital;...

Continue Reading
Sidus Gains Argotec Order, but Investors Need the Math

Updated Category News Views 149

A Real Customer Signal, Minus the Revenue Figure An updated image is the least interesting detail in this release. Sidus Space has landed a purchase order from Argotec Group to manufacture cable assemblies for the HAWK satellite platform, with delivery expected in the first quarter of 2027. That is a legitimate operational win for NASDAQ:SIDU. It brings in a new...

Continue Reading
Saturn and Tileward Put GPU Memory Back to Work Now

Updated Category News Views 49

GPU memory is the tollbooth nobody notices until the whole AI highway backs up. Saturn Cloud’s new partnership with Tileward goes straight at that constraint: use compressed open-model weights, free memory on hardware already installed, and turn that reclaimed capacity into more tokens that an operator can actually sell. It is not glamorous. It may be one of the more...

Continue Reading
Midterm Voters Put Cost Relief Ahead of Washington Wars

Updated Category News Views 78

Gas pumps and medical bills have a way of humiliating every grand political slogan ever printed. Seven Letter Insight's latest post-election survey says confirmed 2026 midterm voters want the 120th Congress to deal with costs first, particularly gas prices, health care, restoring health care tax credits and energy bills. That is not a glamorous mandate. It is, however,...

Continue Reading
Delayed Remodels Can Quietly Drain Your Home's Value

Updated Category News Views 73

A pinhole leak has a nasty talent for becoming a demolition budget. That is the plain lesson in Jason Marks' discussion of delayed remodeling for homeowners in Kernersville, North Carolina. People tend to see a worn bathroom, tired kitchen, or drafty window and think, “Not pretty, but it can wait.” Sometimes it can. Sometimes that little delay lets water, rot,...

Continue Reading
Tampa General's Food Bet Earns a 2026 Innovation Award

Updated Category News Views 41

Hospital meals have long been the punchline nobody bothered to fix, which is why Tampa General Hospital's latest recognition deserves a closer look. The not-for-profit academic health system was named the 2026 Inno Pick by the Tampa Bay Business Journal for its Food as Medicine initiative, its fifth straight year landing among the publication's Inno Award honorees. Awards...

Continue Reading

Top 5 Most Recently Viewed Articles

Ivalua Celebrates Winning Multiple Best Company Awards

Updated Category News Views 104

Ivalua Celebrates Its Recognition with Multiple Best Company Awards Ivalua, a leader in spend management solutions, is excited to share its recent achievements at the Comparably Awards. The company received accolades for Happiest Employees, Best Company Perks & Benefits, and Best Company Work-Life Balance. This recognition underscores Ivalua's commitment to creating an...

Continue Reading
Global Peace Index Reveals Increasing Conflict Trends

Updated Category News Views 371

The 2025 Global Peace Index: A Rising Tide of Conflict The recently released 2025 Global Peace Index (GPI) by the Institute for Economics & Peace (IEP) highlights a troubling trend of declining global peacefulness. The report indicates that we are witnessing a significant change in the global landscape, pointing to a stark reality where conditions leading to conflict are...

Continue Reading
Innovative Device Revolutionizes Painting Techniques and Efficiency

Updated Category News Views 227

Transformative Invention for Painters In the world of painting, efficiency and effectiveness are paramount. Inventors continually seek ways to improve the tools that workers use. One new device, the LOCK & ROLL, aims to enhance the painting experience significantly. Introduction to the LOCK & ROLL This innovative invention is designed to securely anchor paint rollers atop...

Continue Reading
Norfolk Southern's Leadership Crisis: Alan Shaw's Upcoming Exit

Updated Category News Views 130

Norfolk Southern at a Crossroads as Alan Shaw Faces Scrutiny Norfolk Southern Corporation is navigating a tense moment. Chief Executive Alan Shaw is under investigation for alleged ethical violations, including a purported relationship with a company employee. The review has raised questions about leadership, culture, and what accountability should look like at one of the...

Continue Reading
West USA Realty Partners with Zillow to Enhance Listings

Updated Category News Views 235

West USA Realty Embraces Transparency with Zillow West USA Realty, a leading name in the real estate industry, is taking a bold step by aligning with Zillow's standards for consumer access to property listings. This partnership reflects a mutual commitment to transparency and aims to enhance the experience for home buyers and sellers alike. Commitment to Consumers As the...

Continue Reading